Delivery is the Key
A new reality in genetic medicine lies ahead, one in which we can prevent or cure diseases by addressing the problem at its source. This transformation is driven by advancements from companies like Entos Pharmaceuticals, which focus on next generation delivery systems. The key to this progress is the development of safe, effective, and redosable nucleic acid delivery technology that ensures precise biodistribution.
The Fusogenix PLV Platform
Enabling tomorrow’s genetic medicines today, the Fusogenix PLV platform, developed by Entos Pharmaceuticals, utilizes our FAST fusion protein technology. This next generation delivery system allows for delivery by direct fusion, enabling us to create genetic medicines that ensure precise biodistribution, are safe, effective, and redosable.
Precision Targeting
Targeted delivery by FOCUS-AI and AIM
Our optimized platform at Entos Pharmaceuticals utilizes AI to facilitate a next generation delivery system, enabling the highly targeted delivery of genetic medicine to organs, tissues, and cells beyond the liver, ensuring precise biodistribution.
Pipeline and Partners
Enabling genetic cures for all, Entos Pharmaceuticals develops precision nucleic acid therapies that address key clinical unmet needs. Our focus is on genetic medicine, utilizing a next generation delivery system to ensure precise biodistribution of our treatments.
News and Publications
Stay up-to-date with the latest developments in genetic medicine at Entos Pharmaceuticals, where we focus on next generation delivery systems and precise biodistribution.
Our Valued Partners
